Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan

CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.

pills in shape of dollar sign
CBO says Senate insulin bill would raise the diabetes drug’s net price. • Source: Shutterstock

A Senate plan to tackle patient cost-sharing for insulin is estimated to increase the federal deficit by $23.3 bn over a decade, about double the impact of the insulin-provisions in a similar House bill.

The difference is largely due to pharma-friendly elements of the Senate bill that would among other things increase the average...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

Lilly’s Direct-To-Consumer Portal Implicated In Texas Anti-Kickback Suit

 
• By 

Complaint names LillyDirect in action targeting the company’s free nurse and reimbursement support programs for health care providers.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By 

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.

With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight

 
• By 

AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By 

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.

More from Market Access

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

Dutch HTA Calls For “Socially Acceptable” Price For Gene Editing Therapy Casgevy

 

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By 

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.